HC Wainwright's Kapoor talks if Sarepta shares could hit $0

All right. Well, Surrept is sliding again today and down almost 40% in the last two sessions after reporting a third death linked to its gene therapy portfolio. HC Wayright analysts cutting their price target to $0 today.0 saying they expect Seruptus Duchen musculardrophe drug to be taken off the market leaving no intrinsic value in the stock. Mitchell Kapor is behind the call. He's a senior biotech analyst at HC Wayright.He joins us now. Mitchell, great to have you with us. Thank you Melissa.When you say t ...